Evidence map›Paper›PMID 29855362›Full record

ArticleBMC cancer2018

The outcomes and prognostic factors in patients with osteosarcoma according to age: a Japanese nationwide study with focusing on the age differences.

Yusuke Tsuda, Koichi Ogura, Yusuke Shinoda, Hiroshi Kobayashi, Sakae Tanaka, Akira Kawai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Short Latency Radiation Induced Osteosarcoma Detected onMolecular imaging and radionuclide therapy · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Oncological and endoprosthetic outcomes of bone sarcoma patients: a nationwide cohort study.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2020
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yusuke TsudaDepartment of Orthopedic Surgery, University of Tokyo, 3-7-1 Hongo, Bunkyo-ku, Tokyo, Japan.ORCID http://orcid.org/0000-0002-2404-7714
Koichi OguraDepartment of Orthopedic Surgery, University of Tokyo, 3-7-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Yusuke ShinodaDepartment of Orthopedic Surgery, University of Tokyo, 3-7-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Hiroshi KobayashiDepartment of Orthopedic Surgery, University of Tokyo, 3-7-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Sakae TanakaDepartment of Orthopedic Surgery, University of Tokyo, 3-7-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Akira KawaiDepartment of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. akawai@ncc.go.jp.
The University of Tokyo · JPNational Cancer Centre Japan · JP

Funding

National Cancer Center Research and Development Fund 28-A-16
6 · The paper itself

Abstract

backgroundFew reports have described clinical features, prognosis and prognostic factors of osteosarcoma patients according to age.

methodsUsing the Bone and Soft Tissue Tumor Registry in Japan, we identified 1043 osteosarcoma patients including 760 who were younger than 40 years, 173 aged between 41 and 64 years, and 110 patients older than 65 years. We extracted data on patient demographics and prognosis. Prognostic factors for patients older than 65 years or other age groups were analyzed.

resultsPatients older than 65 years showed a significantly higher proportion of tumors arising in the trunk and with metastasis at diagnosis, and their 5-year disease-specific survival (DSS) rate was 32.7%. Multivariate analysis showed that the presence of metastasis at diagnosis [hazard ratio (HR): 3.04; 95% confidence interval (CI), 1.63-5.69; P < 0.001] and tumors > 16 cm in size (HR: 2.84 compared with < 8 cm; 95% CI, 1.16-6.97; P = 0.023) were significantly associated with worse DSS. The 5-year DSS was 39.1% in 80 patients older than 65 years without metastasis at diagnosis. Methotrexate was used in only 5.0% of these patients. Adjuvant chemotherapy was not significantly associated with better DSS (P = 0.323) in this generation and aged between 41 and 64 years (P = 0.566), although adjuvant chemotherapy yielded significantly better survival in patients younger than 40 years (P < 0.001).

conclusionsAnalysis of this cohort of osteosarcoma patients revealed some unique clinical, therapeutic and prognostic features according to age groups in the largest cohort. Adjuvant chemotherapy was not associated with a better DSS in the group of patients aged between 41 and 64 years or older than 65 years.

Indexed as

AdolescentAdultAgedAged, 80 and overAge FactorsAntimetabolites, AntineoplasticBone NeoplasmsChemotherapy, AdjuvantChildChild, PreschoolFemaleHumansJapanKaplan-Meier EstimateMaleMethotrexateAntimetabolites, AntineoplasticMethotrexateAdjuvant chemotherapyElderlyOsteosarcomaPrognosisPrognostic factor

Identifiers

PMID29855362
PMCPMC5984426
OpenAlexW2805822331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.